A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Results (n=25) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 30 May 2018 Planned primary completion date changed from 31 Mar 2018 to 31 Dec 2018.